Moors & Cabot’s CRISPR Therapeutics CRSP Stock Holding History

Moors & Cabot’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$236K	Sell	4,957 -90	-2%	-$4.75K	0.01%	805
2025 Q4	$265K	Sell	5,047 -108	-2%	-$6.47K	0.01%	737
2025 Q3	$334K	Sell	5,155 -300	-5%	-$17.2K	0.01%	636
2025 Q2	$265K	Buy	+5,455	New	+$211K	0.01%	696
2024 Q2	–	Sell	-2,963	Closed	-$202K	–	881
2024 Q1	$202K	Sell	2,963 -620	-17%	-$44.4K	0.01%	813
2023 Q4	$224K	Buy	+3,583	New	+$198K	0.01%	715
2021 Q4	–	Sell	-2,035	Closed	-$228K	–	913
2021 Q3	$228K	Buy	2,035 +150	+8%	+$18.8K	0.01%	704
2021 Q2	$305K	Buy	1,885 +145	+8%	+$17.6K	0.02%	561
2021 Q1	$212K	Buy	+1,740	New	+$263K	0.02%	663

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Moors & Cabot's CRSP Position: Q1 2026 in Review

Moors & Cabot reduced its CRISPR Therapeutics (CRSP) stake by 1.8% in Q1 2026, selling an estimated $4.75K and leaving 4,957 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #805.

Moors & Cabot first reported a position in CRSP in Q1 2021 and has held it in 9 quarters since. The position peaked at $334K in Q3 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Moors & Cabot held 4,957 shares of CRISPR Therapeutics worth $236K as of Q1 2026.
Moors & Cabot sold 90 CRISPR Therapeutics shares in Q1 2026, an estimated $4.75K.
CRISPR Therapeutics made up 0.01% of Moors & Cabot's portfolio in Q1 2026, its #805 holding.
Moors & Cabot first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 9 quarters since.
Moors & Cabot's CRISPR Therapeutics position peaked at $334K in Q3 2025.
490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.